.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Citi
Cipla
Fish and Richardson
Mallinckrodt
US Army
Queensland Health
Cantor Fitzgerald
Fuji

Generated: December 12, 2017

DrugPatentWatch Database Preview

Canagliflozin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for canagliflozin and what is the scope of canagliflozin patent protection?

Canagliflozin
is the generic ingredient in three branded drugs marketed by Janssen Pharms and is included in three NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Canagliflozin has two hundred and three patent family members in forty-two countries and twelve supplementary protection certificates in ten countries.

There are nineteen drug master file entries for canagliflozin. One supplier is listed for this compound.

Medical Subject Heading (MeSH) Categories for canagliflozin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Janssen PharmsINVOKAMETcanagliflozin; metformin hydrochlorideTABLET;ORAL204353-001Aug 8, 2014RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Janssen PharmsINVOKANAcanagliflozinTABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsINVOKAMET XRcanagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205879-001Sep 20, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Janssen PharmsINVOKAMET XRcanagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205879-003Sep 20, 2016RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsINVOKAMETcanagliflozin; metformin hydrochlorideTABLET;ORAL204353-004Aug 8, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Janssen PharmsINVOKAMETcanagliflozin; metformin hydrochlorideTABLET;ORAL204353-001Aug 8, 2014RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsINVOKAMET XRcanagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205879-004Sep 20, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Janssen PharmsINVOKANAcanagliflozinTABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Janssen PharmsINVOKAMETcanagliflozin; metformin hydrochlorideTABLET;ORAL204353-004Aug 8, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Janssen PharmsINVOKAMET XRcanagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205879-003Sep 20, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: canagliflozin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,511,021Substituted indazole-O-glucosides► Subscribe
8,202,984Glucopyranoside compound► Subscribe
7,816,331Substituted indazole-O-glucosides► Subscribe
7,084,124Substituted indazole-O-glucosides► Subscribe
7,511,022Substituted indole-O-glucosides► Subscribe
7,820,630Substituted indole-O-glucosides► Subscribe
7,521,430N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter► Subscribe
7,511,020Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides► Subscribe
7,129,220Substituted indole-O-glucosides► Subscribe
7,816,328Substituted fused heterocyclic C-glycosides► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: canagliflozin

Country Document Number Estimated Expiration
Israel175491► Subscribe
Argentina048375► Subscribe
Eurasian Patent Organization011515► Subscribe
Japan2007518683► Subscribe
Israel175489► Subscribe
Canada2671357► Subscribe
EcuadorSP066627► Subscribe
European Patent Office2514756► Subscribe
Iceland8444► Subscribe
Guatemala200900151► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CANAGLIFLOZIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0140011 00102Estonia► SubscribePRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013
2014008Lithuania► SubscribePRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013 11 15 EU/1/13/884/005 - EU/1/13/884/008 20131115
4 1-2014Slovakia► SubscribePRODUCT NAME: KANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/008 20131115
2014 00024Denmark► SubscribePRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115
2014000050Germany► SubscribePRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1 /13/884/001-008 20131115
14/029Ireland► SubscribePRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001-004 20131119
00670Netherlands► SubscribePRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118
90027-8Sweden► SubscribePRODUCT NAME: KANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001 20131115
C0034France► SubscribePRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131115
0670Netherlands► SubscribePRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
Johnson and Johnson
Fuji
Mallinckrodt
Queensland Health
Covington
Chubb
Accenture
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot